Search our Database of Scientific Publications and Authors

I’m looking for a
    [New therapeutic schedules of Sunitinib: Current evidence regarding the 2:1 scheme.]
    Arch Esp Urol 2017 Apr;70(3):336-341
    UGC Urología. Complejo Hospitalario Universitario Granada (CHUG). Instituto de Investigación Biosanitaria IBS. Granada. Universidad de Granada. España.
    Introduction: In 2006, sunitinib approval by the FDA was a real revolution for the treatment of metastatic renal cell carcinoma (mRCC). However, considerable rates of dose reductions and therapeutic suppressions with the standard regimen (4:2) have forced the search for new schedule proposals in order to optimize the balance between side effects and oncologic efficacy. Among these new proposals, the 2:1 scheme is the one that has generated more expectations.

    Objective: The objective of this paper is to make a review and critical discussion of current evidence about the new schedules of treatment with sunitinib.

    Methods: Unstructured review of the literature on the various therapeutic regimens with sunitinib, making a comparison in terms of progression-free survival (PFS), overall survival (OS) and toxicity.

    Results: We summarize the data from all relevant studies published to date comparing the standard 4:2 schedule versus the new 2:1. Most patients treated with 2:1 scheme are grouped in three retrospective observational studies and mostly correspond to patients who were initially treated with a 4:2 scheme and then moved to 2:1. A phase II randomized clinical trial comparing 4:2 and 2:1 schemes from the beginning has also been conducted. None of these studies found significant differences between the two regimens in terms of PFS or OS. Regarding the toxicity profile, the 2:1 scheme has proved to be more advantageous than the 4:2.

    Conclusions: Despite the still limited amount of data, current evidence supports the use of a 2:1 schedule, as it provides patients substantial advantages because of its better tolerability profile, without a loss in oncological efficacy. Currently, the 2:1 scheme is an appropriate alternative therapeutic strategy, especially in patients with poor tolerance to the standard 4:2 regimen.

    Similar Publications

    [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
    Bull Cancer 2014 Sep;101(9):832-40
    Oncologie médicale, Hôpital Saint-André, 33000 Bordeaux, France, Early Drug Development Certified Unit (Inserm-CIC/INCa), 33075 Bordeaux, France.
    Sunitinib was the first targeted therapy improving progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) in the first line of treatment. Classically, sunitinib is administered at a dose of 50 mg/day during four weeks followed by two weeks off (schedule 4/6). This schedule has two pitfalls: intermittent exposure with two weeks "off" and the increase in toxicity during the fourth week. Read More
    Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    J Clin Oncol 2009 Sep 3;27(25):4068-75. Epub 2009 Aug 3.
    Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France.
    Purpose: Sunitinib has demonstrated antitumor activity in metastatic renal cell carcinoma (mRCC) when given at 50 mg/d on a 4-weeks-on 2-weeks-off regimen. Herein, we report results of an open-label, multicenter phase II mRCC study of sunitinib administered on a continuous once-daily dosing regimen.

    Patients And Methods: Eligibility criteria included histologically proven mRCC with measurable disease, failure of one prior cytokine regimen, and good performance status. Read More
    The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Eur Urol 2011 Sep 17;60(3):448-54. Epub 2011 May 17.
    Bart Cancer Institute, Queen Mary University of London, St Bartholomew's Hospital London, UK.
    Background: The role of cytoreductive nephrectomy in metastatic clear cell renal cell carcinoma (ccRCC) is controversial.

    Objective: To determine the outcome of patients with metastatic ccRCC who receive sunitinib prior to planned nephrectomy.

    Design, Setting, And Participants: The study combined the data from two prospective phase 2 studies that assessed upfront sunitinib (12-16 wk) prior to nephrectomy in previously untreated patients with metastatic renal cell carcinoma (RCC). Read More
    Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
    Ann Oncol 2015 Oct 27;26(10):2107-13. Epub 2015 Jul 27.
    Institut Gustave Roussy/Medical Oncology Department, Paris, France.
    Background: First-line sunitinib is recommended in metastatic renal cell carcinoma (mRCC), but it is frequently associated with relevant toxicities and subsequent dose reductions. Alternative schedules, such as 2-week-on treatment and 1-week-off (2/1 schedule), might improve tolerability. We evaluated the safety and outcomes of this schedule in a large multicenter analysis. Read More